Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy

J Infect Dis. 1999 Oct;180(4):1057-63. doi: 10.1086/315025.

Abstract

The present study investigated immune restoration in patients at intermediate stages of human immunodeficiency virus (HIV) disease after initiation of highly active antiretroviral therapy (HAART). A progressive increase in both memory and naive CD4+ T cells was observed from the first weeks of therapy, concomitant with a decrease in the expression of activation markers on CD8+ T cells. The early-activation marker CD69 remained, however, overexpressed on T cells after suboptimal stimulation in vitro, indicative of persistent immune activation. The percentage of interleukin (IL)-2-producing CD4+ T cells significantly increased from 9 months of HAART. In most patients, CD4+ T cells recovered an ability to produce IL-2 on stimulation, similar to that of HIV-seronegative controls. Reversal of T-cell anergy may be a key event in immune restoration for achieving long-term clinical benefit with HAART.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD / blood
  • Antigens, Differentiation, T-Lymphocyte / blood
  • Antiviral Agents / therapeutic use*
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology*
  • Drug Therapy, Combination
  • Follow-Up Studies
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • Humans
  • Immunologic Memory
  • Immunophenotyping
  • Interleukin-2 / biosynthesis*
  • Lectins, C-Type
  • Lymphocyte Activation
  • Middle Aged
  • Monitoring, Immunologic
  • T-Lymphocytes / immunology*
  • Time Factors

Substances

  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • Antiviral Agents
  • Biomarkers
  • CD69 antigen
  • Interleukin-2
  • Lectins, C-Type